Compare Stocks → Trump’s “Tax Free” Retirement Strategy (From Gold Safe Exchange) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:AYLANASDAQ:BCLINASDAQ:GMDANASDAQ:MIRONYSE:RCOR Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAYLAAyala Pharmaceuticals$0.50+5.8%$0.48$0.36▼$7.31$7.46M1.9876,300 shs137,700 shsBCLIBrainstorm Cell Therapeutics$0.56-6.6%$0.37$0.13▼$3.46$27.66M0.22962,356 shs647,340 shsGMDAGamida Cell$0.04-35.7%$0.36$0.03▼$2.51$3.81M1.036.27 million shs88.26 million shsMIROMiromatrix Medical$3.39+0.6%$3.38$0.91▼$4.35$92.95M0.0180,095 shs632,100 shsRCORRenovacor$3.20$3.07$1.34▼$9.74$55.26M-0.2830,033 shsN/A12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAYLAAyala Pharmaceuticals0.00%0.00%0.00%0.00%0.00%BCLIBrainstorm Cell Therapeutics-9.06%+18.38%+67.23%+127.18%-67.38%GMDAGamida Cell-82.74%-84.26%-84.42%-85.28%-92.24%MIROMiromatrix Medical0.00%0.00%0.00%0.00%+114.56%RCORRenovacor0.00%0.00%0.00%0.00%0.00%AI Cracks Open Largest Untapped Energy Reserve on Earth (Ad)This orb represents the largest untapped energy source in the world… And although this energy resource is unknown by 99% of the public… It makes gas, coal, oil, wind, hydropower, solar, fusion… ]click here to watch a free presentation where I reveal all the details of this lucrative opportunitMarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAYLAAyala PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/ABCLIBrainstorm Cell Therapeutics4.3612 of 5 stars3.05.00.04.73.80.00.6GMDAGamida Cell1.4818 of 5 stars3.42.00.00.02.20.80.6MIROMiromatrix MedicalN/AN/AN/AN/AN/AN/AN/AN/ARCORRenovacorN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAYLAAyala PharmaceuticalsN/AN/AN/AN/ABCLIBrainstorm Cell Therapeutics2.00Hold$10.001,670.85% UpsideGMDAGamida Cell2.75Moderate Buy$4.7513,057.89% UpsideMIROMiromatrix Medical3.00Buy$3.00-11.50% DownsideRCORRenovacorN/AN/AN/AN/ACurrent Analyst RatingsLatest AYLA, MIRO, RCOR, BCLI, and GMDA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails1/29/2024GMDAGamida CellJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Outperform ➝ Market Perform(Data available from 3/28/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAYLAAyala Pharmaceuticals$3.51M2.13N/AN/A$2.45 per share0.21BCLIBrainstorm Cell TherapeuticsN/AN/AN/AN/A($0.08) per shareN/AGMDAGamida CellN/AN/AN/AN/A($0.11) per shareN/AMIROMiromatrix Medical$958.03K97.02N/AN/A$1.25 per share2.71RCORRenovacorN/AN/AN/AN/A$2.47 per shareN/AProfitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAYLAAyala Pharmaceuticals-$40.25M-$2.52N/AN/AN/A-2,341.69%-182.13%-139.83%N/ABCLIBrainstorm Cell Therapeutics-$24.28M-$0.44N/AN/AN/AN/AN/A-310.78%4/4/2024 (Estimated)GMDAGamida Cell-$79.38M-$0.30N/AN/AN/AN/AN/A-66.89%5/20/2024 (Estimated)MIROMiromatrix Medical-$29.96M-$1.14N/A∞N/A-2,861.17%-120.49%-90.70%3/29/2024 (Estimated)RCORRenovacor-$14.10M-$0.73N/AN/AN/AN/A-62.88%-48.90%N/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAYLAAyala PharmaceuticalsN/AN/AN/AN/AN/ABCLIBrainstorm Cell TherapeuticsN/AN/AN/AN/AN/AGMDAGamida CellN/AN/AN/AN/AN/AMIROMiromatrix MedicalN/AN/AN/AN/AN/ARCORRenovacorN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAYLAAyala PharmaceuticalsN/A2.282.28BCLIBrainstorm Cell TherapeuticsN/A0.240.24GMDAGamida Cell213.143.323.20MIROMiromatrix Medical0.023.463.46RCORRenovacorN/A6.606.60OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAYLAAyala Pharmaceuticals22.10%BCLIBrainstorm Cell Therapeutics14.33%GMDAGamida Cell50.34%MIROMiromatrix Medical29.38%RCORRenovacor45.84%Insider OwnershipCompanyInsider OwnershipAYLAAyala Pharmaceuticals3.60%BCLIBrainstorm Cell Therapeutics5.45%GMDAGamida Cell3.40%MIROMiromatrix Medical5.20%RCORRenovacor14.40%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableAYLAAyala Pharmaceuticals3514.82 million14.29 millionNot OptionableBCLIBrainstorm Cell Therapeutics4248.98 million46.31 millionOptionableGMDAGamida Cell143105.59 million102.00 millionOptionableMIROMiromatrix Medical7627.42 million25.99 millionOptionableRCORRenovacor1917.27 million14.78 millionNot OptionableAYLA, MIRO, RCOR, BCLI, and GMDA HeadlinesSourceHeadlineNHL opening night delivers record viewership on ESPNnhl.com - November 6 at 5:27 PMState Pension payments worth over £2,000 each month for older people living in these European countriesdailyrecord.co.uk - October 30 at 1:55 PMThe best early Black Friday turntable deals 2023whathifi.com - October 29 at 12:00 AMAnas Sarwar 'unhappy' with Keir Starmer over Labour leader's response to Gaza crisisdailyrecord.co.uk - October 27 at 2:36 PMNYC shoplifting hit record highs last year: ‘We can’t stop them’nypost.com - October 24 at 1:35 PMTranscriptional control of the inflammatory responsenature.com - October 18 at 7:59 AMRockwell Medical Appoints Joan Lau, Ph.D. to the Company's Board of Directorsfinance.yahoo.com - October 17 at 7:56 AMFolwell criticizes fellow Republicans on public records rollbackwral.com - October 14 at 8:16 PMBest Bluetooth turntables 2023: wireless record players for streaming vinylwhathifi.com - October 11 at 12:09 PMHere’s why you shouldn’t record meltdowns on an airplane: FAA insidernypost.com - October 3 at 11:57 PMRecord-breaking heat wave peaking in Eastern U.S. with highs near 100washingtonpost.com - September 28 at 6:28 PMiOS 17: How to Record a FaceTime Video or Audio Messagemacrumors.com - September 15 at 7:16 PMThis was the world’s hottest summer on record ‘by a large margin’washingtonpost.com - September 9 at 6:12 PMCapCut breaths life into new-wave blogging for modern businessesdailyrecord.co.uk - September 6 at 9:28 AMMontauk trailer listing eyes record — even with a price cuttherealdeal.com - September 5 at 11:26 PMRecord-Breaking Summer: Portland, New Orleans Break Daily High Temperature Records After Hottest July Everforbes.com - August 23 at 10:13 AMRecord-Breaking Summer: Jacksonville, Miami Break Daily High Temperature Records, After Hottest July Everforbes.com - August 16 at 6:56 PMPhoenix, New Orleans, Baton Rouge Break Daily High Temperature Records: Here’s Where Else Daily Records Have Fallenforbes.com - August 11 at 7:09 PMPhoenix, Dallas, Little Rock Break Daily High Temperature Records: Here’s Where Else Daily Records Have Fallenforbes.com - August 9 at 12:55 AMPhoenix just posted the hottest month ever observed in a U.S. citywashingtonpost.com - August 5 at 9:27 AMAcademic Recordsdrexel.edu - July 27 at 12:31 AMAfter Earth's hottest week on record, extreme weather surprises everyone — even climate scientistscbc.ca - July 25 at 5:27 PMRecord Highgrist.org - July 22 at 5:01 PMPhoenix, Salt Lake City Set High Temperature Records: Here’s Where Else Records Could Fallforbes.com - July 20 at 6:06 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsAyala PharmaceuticalsNASDAQ:AYLAAyala Pharmaceuticals, Inc., a clinical-stage oncology company, focuses on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers. The company's lead product candidate is AL101, a potent, selective, and injectable small molecule gamma secretase inhibitor (GSI) that is in Phase II clinical trial for the treatment of recurrent/metastatic adenoid cystic carcinoma for patients bearing Notch-activating mutations. It is also involved in developing AL102, a potent, selective, and oral small molecule GSI that is in Phase II/III pivotal study for the treatment of desmoid tumors. Ayala Pharmaceuticals, Inc. has a collaboration agreement with Novartis International Pharmaceutical Limited to develop AL102 for the treatment of multiple myeloma. The company was incorporated in 2017 and is headquartered in Rehovot, Israel.Brainstorm Cell TherapeuticsNASDAQ:BCLIBrainstorm Cell Therapeutics Inc., a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function. It is developing NurOwn, which has completed Phase III clinical trial for the treatment of amyotrophic lateral sclerosis; Phase II clinical trial for the treatment of progressive multiple sclerosis; and for the treatment of alzheimer's disease, as well as for other neurodegenerative diseases. The company was formerly known as Golden Hand Resources Inc. and changed its name to Brainstorm Cell Therapeutics Inc. in November 2004. Brainstorm Cell Therapeutics Inc. was incorporated in 2000 and is headquartered in New York, New York.Gamida CellNASDAQ:GMDAGamida Cell Ltd., a clinical-stage biopharmaceutical company, develops cell therapies to cure blood cancers and serious blood diseases. The company's lead product candidate is omidubicel, a cell therapy that has completed Phase III clinical trial in patients with hematologic malignancies, as well as in Phase II clinical trials in patients with severe aplastic anemia. It is also developing GDA-201, an investigational NK cell-based cancer immunotherapy, which is in Phase I/II studies for the treatment of relapsed or refractory non-Hodgkin lymphoma and multiple myeloma. The company was incorporated in 1998 and is headquartered in Jerusalem, Israel.Miromatrix MedicalNASDAQ:MIROMiromatrix Medical Inc., a life sciences company, develops a novel technology for bioengineering fully transplantable organs. The company's proprietary technology is a platform that uses a two-step method of decellularization and recellularization designed to remove the porcine cells from the organs obtained from pigs and replace them with unmodified human cells. It has collaborations with Baxter, CareDx, The Mayo Clinic, Mount Sinai Hospital, and The Texas Heart Institute. The company was formerly known as TayTech, Inc. Miromatrix Medical Inc. was incorporated in 2009 and is headquartered in Eden Prairie, Minnesota.RenovacorNYSE:RCORRenovacor, Inc., a biotechnology company, focuses on delivering various precision therapies to enhance the lives of patients and families battling genetically-driven cardiovascular and mechanistically-related diseases. It primarily focuses on the treatment of BCL2-associated athanogene 3 (BAG3) mutation-associated dilated cardiomyopathy (DCM). The company's lead product candidate is REN-001, a recombinant adeno-associated virus 9-based gene therapy designed to deliver a functional BAG3 gene to augment BAG3 protein levels in cardiomyocytes, and slow or halt progression of BAG3 DCM. It is also developing a pipeline of BAG3-associated gene therapies for diseases with high unmet medical need associated with mutations in the BAG3 gene and mechanistically linked to BAG3's expression and function. The company was founded in 2013 and is based in Greenwich, Connecticut. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.